1132667-41-4

Upstream product

• 1043577-31-6 (S,E)-2-(trimethylsilyl)ethyl 3-(((S)-2-amino-3-methylbutanoyl)oxy)-7-(tritylthio)hept-4-enoate 
• 71989-31-6 Fmoc-Pro-OH 
• 1205666-87-0 C₃₈H₃₉NO₂S₃ 
• 3695-77-0 triphenylmethanethiol 
• 542-28-9 3,4,5,6-tetrahydro-2H-pyran-2-one 
• 2916-68-9 2-(Trimethylsilyl)ethanol 
• 180973-22-2 (2E)-5-[(triphenylmethyl)thio]-2-pentenal 

Downstream Products

• 1132667-42-5 C₅₀H₆₂N₄O₇S₃Si 

Relevant academic research and scientific papers

METHOD FOR PREPARING LARGAZOLE ANALOGS AND USES THEREOF

Analogs of largazole are described herein. Methods of treating cancer and blood disorders using largazole and largazole analogs and pharmaceutical compositions comprising the same are additionally described herein. Methods for preparing largazole analogs are likewise described.

Method for preparing largazole analogs and uses thereof

Analogs of largazole are described herein. Methods of treating cancer and blood disorders using largazole and largazole analogs and pharmaceutical compositions comprising the same are additionally described herein. Methods for preparing largazole analogs are likewise described.

Synthesis and histone deacetylase inhibitory activity of largazole analogs: Alteration of the zinc-binding domain and macrocyclic scaffold

Fourteen analogs of the marine natural product largazole have been prepared and assayed against histone deacetylases (HDACs) 1, 2, 3, and 6. Olefin cross-metathesis was used to efficiently access six variants of the side-chain zinc-binding domain, while adaptation of our previously reported modular synthesis allowed probing of the macrocyclic cap group.